release criteria up to 7 d of storage, this treatment results in considerable metabolic deterioration, increased platelet activation during storage and inconsistent findings by in vitro haemostatic assessment (Van Rhenen et al, 2000; Janetzko et al, 2004; Jansen et al, 2004; Picker et al, 2004; Apelseth et al, 2007; Lozano et al, 2007; van der Meer et al, 2009) . Nevertheless, transfusion in thrombocytopenic patients corrected prolonged bleeding times . Radiolabeled, autologous amotosalen-HCl/UVA-treated platelets stored for 5 d showed a significant lower recovery and reduction in survival time as compared to platelets stored in platelet additive solution III (PASIII) . Three randomized controlled trials have been performed using amotosalen-HCl/UVA-treated platelet concentrates (PC) (van Rhenen et al, 2003; McCullough et al, 2004; Janetzko et al, 2005) . In the S-59 Platelet Recovery in Thrombocytopenia (SPRINT) trial (645 patients), that used aphaeresis PC stored in plasma as control, significantly lower post transfusion platelet increments were found, combined with a reduced transfusion interval and an increased rate of transfusion failure (McCullough et al, 2004) . The S-59 Platelet Recovery in Thrombocytopenia in Europe (EuroSPRITE) trial (103 patients) reported no significant differences with regard to transfusion efficacy, however the control arm of this study used buffy-coat derived platelets stored in plasma as well as in additive solution (PASII) for approximately half of the transfusions (van Rhenen et al, 2003) . In a previous randomized clinical trial (RCT) we showed that PASII PC have a 20% lower corrected count increment (CCI) as compared to plasma PC, which might mask a relevant difference (Kerkhoffs et al, 2006) . A third small trial with 43 patients showed a borderline significant reduction in transfusion efficacy (Janetzko et al, 2005) . None of these trials reported inferior haemostatic efficacy. Before implementing PR platelet products, extension of the storage time to 7 d while maintaining clinical efficacy is an important aspect to compensate for the additional costs of the procedure. We performed a multicentre open-label, randomized clinical trial to study the clinical efficacy, in terms of transfusion response, of pooled, random donor PC stored for up to 7 d in platelet additive solution (Intersol, Fenwal, Inc., Lake Zurich, IL, USA) without additional PR (PASIII) and with amotosalen-HCl/UVA photochemical PR (PR-PAS-III, Intercept Blood System, Cerus Corporation, Concord, CA, USA), compared to platelets stored in plasma.
Methods

Study design
The study was designed as a prospective, randomized openlabel non-inferiority trial in haemato-oncological patients with thrombocytopenia or expected to be thrombocytopenic caused by myelosuppression. Patients were recruited from the haematology wards of eight Dutch hospitals. The study protocol and consent forms were approved both by a central ethics committee as well as local institutional review boards. The study was conducted according to the International Conference on Harmonization/World Health Organization (WHO) Good Clinical Practice (ICH-GCP) guidelines and the declaration of Helsinki. During the study all centres were audited and trial conduct was monitored by an independent organization. All adult patients (aged >18 years) with a haemato-oncological disease were eligible for inclusion if they were expected to receive 2 or more platelet transfusions. Exclusion criteria were immunological refractoriness to random platelet transfusions due to human leucocyte antigen (HLA)-and/or human platelet antigen (HPA)-antibodies or clinical relevant auto-antibodies, pregnancy (or lactating) and previous inclusion in this study. After informed consent eligible patients were registered and randomized, stratified by centre, before platelet transfusions were started in a 1:1:1 ratio to receive per protocol up to a maximum of five platelet transfusions with Plasma-PC, PASIII-PC or PR-PASIII-PC in a period of maximal 42 d. Off protocol platelet transfusions were allowed during the study period in case of nonavailability of the correct component. Apart from normal completion, reasons to go off study were refusal to continue by the patient or treating physician, intercurrent death and immunological refractoriness.
Platelet products, transfusions and monitoring
All products were produced by the Sanquin Blood Bank. PCs were prepared from five pooled whole-blood buffy-coats (BC) with the same ABO-blood group using standard procedures and with regard to pathogen reduction using manufacturer's instructions (van Rhenen et al, 2003; Kerkhoffs et al, 2006) . Samples were obtained prior to storage to measure platelet content. Samples of all products were cultured for 7 d using the BacT/Alert culturing system (BioMerieux, Boxtel, the Netherlands). All products were stored with gentle agitation at 20-24°C for up to 7 d. The PCs were c-irradiated if requested by the hospital.
Indications for platelet transfusions were divided into platelet count-based prophylaxis, intervention-related prophylaxis and treatment of bleeding. Generally accepted guidelines were used for the indication of platelet transfusions. The requirement for, and timing of platelet transfusion(s) was determined by the treating physician. In summary, in stable, non-bleeding patients a platelet transfusion was advised to maintain the platelet count ‡10 · 10 9 /l and ‡40 · 10 9 /l when these patients received anti-coagulant therapy or treatment with anti-thymocyte globulin. A transfusion trigger platelet count of 40 · 10 9 /l was recommended in endoscopic evaluation of the gastrointestinal or respiratory tract, when no biopsies were performed, diagnostic pleural or peritoneal puncture with a thin needle, lumbar puncture, extraction of a central venous catheter and minor surgical interventions. A trigger platelet count of 60 · 10 9 /l was recommended in case of bleeding, endoscopic evaluation with biopsies, dental extractions, placement of a central venous catheter and major surgical interventions, with the exception of neurosurgery and cardiac surgery. In case of cerebral bleeding, diffuse alveolar haemorrhage, neurosurgery and cardiac surgery, a trigger of 100 · 10 9 /l was recommended. A pretransfusion platelet count was preferably measured just before transfusion up till a maximum of 6 h before transfusion. A 1-h post-transfusion platelet count was measured between 10 and 120 min after transfusion and a 24-h post-transfusion platelet count was measured between 16 and 28 h after transfusion. The CCI was calculated as follows: CCI 1/24 h = [(post-transfusion platelet count 1/24 h -pre-transfusion platelet count (·10 9 /l)) · body surface area (m 2 )]/platelet dose · 10
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. Transfusions given shortly after one another without platelet counts between the transfusions were considered to be multi-dose transfusions and analysed as a single transfusion. If available, ABO-identical PC were used, although minor-and major incompatible PC were not excluded. Platelet transfusion failure was defined as a 1-h CCI below 7AE5 and/or and 24-h CCI below 4AE5 (Kerkhoffs et al, 2006) . Immunological refractoriness was defined as the occurrence of transfusion failure of two consecutive ABOmatched random platelet transfusions combined with the existence of HLA-and/or HPA-alloantibodies.
Study endpoints
The primary endpoint was the 1-h CCI. Secondary endpoints were 24-h CCI, bleeding, the transfusion requirement of red cells and PCs, platelet transfusion interval and adverse transfusion reactions. The following characteristics were recorded at entry: gender, age, blood group, haematological disease and treatment phase, WHO performance status, existence of enlarged spleen, transfusion history, treatment with anti-coagulation, medical history, medication, bleeding and presence of active infection. The following characteristics were recorded at each transfusion: the reason of the transfusion (trigger platelet count, bleeding or intervention), the blood group of the PC, presence of fever, presence of infection (graded according to the Common Toxicity Criteria for Adverse Events, CTCAE, Version 3; http://ctep.cancer.gov/ protocolDevelopment/electronic_applications/docs/ctcaev3. pdf), presence of mucosal damage, and use of acetaminophen, steroids or antihistamines. Patients were evaluated daily by trained personnel to observe, describe and grade bleeding complications at eight defined sites according to the CTCAE under supervision of the local investigator (http://ctep.info.-nih.gov/reporting/ctc.html). Briefly, grade 1 or minor bleeding comprised petechiae, minimal or microscopic bleeding not requiring interventions. Grade 2 bleeding was defined as gross, symptomatic bleeding for which minimal intervention (i.e. aspiration, cauterization, irrigation of the urinary tract) was indicated. Grade 3 was severe bleeding requiring red cell transfusions and/or major interventions. Generalized petechiae/purpura as well as retinal bleeding with visual impairment was also classified as grade 3. Catastrophic bleeding defined grade 4, as did central nervous system (CNS) bleeding causing neurological deficit or disability. Lethal bleeding was classified as grade 5. All major bleeding complications were reviewed centrally. Infections were scored in case of positive cultures or if a focus was likely as shown by clinical or radiological examination. In addition to haematological parameters, prothrombin time, activated partial thromboplastin time and fibrinogen levels were measured regularly. Some centres performed routine periodic serological testing of HLA-and/or HPA-alloantibodies, whereas other centres performed these tests only on indication.
Reporting of serious adverse events and Data Safety Monitoring Board
Serious adverse events (SAE) for the purpose of this study were defined as any untoward medical occurrence that resulted in death, a life-threatening event or any other medical condition that might jeopardize the patient or required intervention to prevent more serious sequelae. SAE reporting was mandatory within 24 h of the initial observation. An independent Data Safety Monitoring Board (DSMB) was installed before the start of the study. An interim analysis was planned after 300 transfusions. All serious adverse events (SAEs) were reviewed by the DSMB. Two criteria for early stopping of an experimental arm were defined: (i) A negative 24-h CCI (decrement) not caused by immunological factors in more than 20% of the transfusions, (ii) Statistically significant more bleeding complications (CTCAE ‡ 2) compared to the Plasma arm.
Power calculation and statistical analysis
The study was designed as a one-sided, non-inferiority study comparing the 1-h CCI of the transfusions in the PR-PASIII and PASIII arms with the Plasma arm. Inferiority of an experimental arm was defined as a 20% lower mean 1-h CCI compared to the Plasma arm. A mean 1-h CCI of 15AE6 and a standard deviation of 6AE0 were used, based on a previous study The study randomization scheme, together with evaluable patients, transfusions and endpoints. n, number of patients, n PC, number of single platelet concentrates, n TRF, number of PC transfusion events (includes pooled transfusions). Of the 17 non-evaluable patients, four were non-eligible due to anti-HLA antibodies and 13 patients did not receive any platelet transfusions, without differences between study groups.
Clinical Effectiveness of Amotosalen-HCl/UVA Treated PC ª 2010 Blackwell Publishing Ltd, British Journal of Haematology (Kerkhoffs et al, 2006) . For a power of 90% and an alpha of 0AE025 (multiple testing) 100 patients per arm were required. In case of multi-dose transfusions, the sum of the platelet content of the PC was used. If one of the PC products differed from the allocated arm, the multi-dose transfusion was considered as not according to protocol. The mean of the storage times of the PC in a multi-dose transfusion was used as the storage time. The 1-and 24-h counts after the infusion of the last PC of a multi-dose transfusion were used for analysis. To account for the hierarchical structure of the data with a variable number of transfusions per patient, the data were analysed using mixed regression models with random effects for patient and transfusion number. Besides the CCIs, 1-and 24-h posttransfusion counts were used as endpoints in regression models with as additional covariates besides arm, platelet dose, pretransfusion counts and body surface area of the patient (Davis et al, 1999) . The data were analysed by intention to treat (ITT) as well as per protocol (PP). To assess safety, the incidence of bleeding complications and adverse reactions were analysed through tabulation. Pearson's chi-square test was used to compare categorical patient characteristics by arm and the Kruskal-Wallis test to compare ordinal or continuous characteristics by arm. The relationship between storage time and the post-transfusion counts and CCIs was assessed by adding this factor as covariate to the regression models. The association between the patient and transfusion characteristics mentioned above was assessed by adding each of these variables separately as covariate to the regression models. All (5) 16 (4) Unknown 4 (1) 3 (1) 4 (1) Platelet product content, mean · 10 11 ± SD 3AE9 ± 1AE0 3 AE6 ± 0AE8 3AE4 ± 0AE8 Storage time, mean days ± SD 4AE0 ± 1AE8 3 AE8 ± 1AE8 4 AE0 ± 1AE6 Pre transfusion platelet count · 10 9 /l ± SD 18 ± 13 17 ± 13 16 ± 11à
Major ABO-incompatibility occurred in only six PC transfusions. AML, acute myeloid leukaemia; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic leukaemia; RBC, red blood cell; PC, platelet concentrate; SD, standard deviation. *Number (%) of evaluable patients and transfusions. P < 0AE001 as compared to plasma. àP = 0AE04 as compared to plasma.
statistical analyses were performed using stata. P values <0AE05 were considered significant.
Results
Patients and platelet transfusions
Patients were included in the study beginning March 2007. The inclusion of patients in the PR-PASIII group was halted after 92 patients in January 2009 on advice of the DSMB because of lower CCI's (P < 0AE0001) and more bleeds (P = 0AE045) compared to the plasma group. Inclusion of patients in the plasma and PASIII group ended in May 2009 and overall 295 patients were randomized. There were 17 non-evaluable patients, resulting in a total of 278 evaluable patients and 1129 transfusion events (Fig 1) . There were no significant differences in the patient characteristics of the study groups (Table I) . A total of 302 transfusion events (27%) were not according to the allocated study arm, more frequent in both study arms. Eighty-five percentage of the offprotocol PC were platelets stored in PASII, 15% were platelets stored in plasma. The study products had a lower platelet content, with a mean difference of 6% and 11% for PASIII-PC and PR-PASIII-PC as compared to plasma PC, respectively (Table I , P < 0AE001).
Platelet transfusion efficacy
All efficacy analyses were done ITT as well as PP. The 1-h CCI and 24-h CCI were evaluable in 1004 (88AE9%) and 1013 (89AE7%) of the transfusion events, respectively. The single reason for a non-evaluable CCI-1/24 h was failure to perform a platelet count after transfusion and, with respect to these missing evaluations, there were no significant differences between the study groups or between the PP and off-protocol transfusion events. All transfusion efficacy parameters showed inferiority of PR-PASIII-PC transfusions. There were no significant differences in transfusion responses between PAS-III-PC and Plasma-PC (Table II) . The proportion PC stored for 6 and 7 d was equally distributed across the arms, being 24%, 21% and 26% of transfused PC in the plasma arm, the PASIII arm and the PRPASIII arm, respectively. Both the 1-and 24-h CCI decreased with longer storage time in all study groups. However both CCIs were significantly less in PR-PASIII-PC at each day of storage as compared to plasma PC (Fig 2A, B) . The 1-and 24-h CCIs of PASIII-PC were not significantly different to those of plasma PC up to 7 d of storage. Linear regression analysis of 1-and 24-h platelet count showed a platelet dose-independent effect of PR (Fig 2C, D , Table III ). A number of product-and patient-related covariates were tested for an association with CCIs, adjusted for arm ITT analysis CCI-1 h, mean ± SD 17AE1 ± 7AE3 1 5 AE3 ± 6AE5 1 1 AE4 ± 5AE3-Mean diff (97AE5% CI)* )9% ()22%; 4%) )31% ()43%; )18%) CCI-24 h, mean ± SD 12AE8 ± 7AE8 1 1 AE6 ± 7AE6 7 AE9 ± 5AE3-Mean difference (97AE5% CI)* )7% ()26%; 12%) )34% ()52%; )17%) PP analysis CCI-1 h, mean ± SD 17AE1 ± 7AE3 1 5 AE3 ± 6AE7 1 0 AE6 ± 5AE0-Mean diff (97AE5% CI)* )10% ()23%; 4%) )36% ()49%; )24%) CCI-24 h, mean ± SD 12AE5 ± 7AE7 1 1 AE7 ± 7AE6 6 AE8 ± 5AE9-Mean difference (97AE5%CI)* )4% ()24%; 16%) )42% ()61%; )23%) Other response parameters (ITT) CI-1 h, mean · 10 9 /l ± SD 34 ± 15 29 ± 13 20 ± 10 § CI-24 h, mean · 10 9 /l ± SD 25 ± 15 21 ± 13 14 ± 10à PC transfusions/patient, mean ± SD 4 ± 2 4 ± 3 5 ± 3 TRF interval (h), mean ± SD 81 ± 47 77 ± 44 61 ± 47à Transfusion failure (ITT) No. of evaluable CCI-1 h 314 340 350 CCI-1 h < 7AE5 (%)** 48 (15) 66 (19) 97 (28) (Tables IV) . Storage time, enlarged spleen and fever were highly significantly associated with lower CCIs, while the use of steroids as premedication was associated with a higher 1-h CCI and transfusion for a bleeding indication was associated with a lower 24-h CCI.
Bleeding and other clinical complications
A total of 67 new bleeding episodes (CTCAE grade 1-3) were observed in 60 patients during the on-study period from the start of the first transfusion, with significantly more (P = 0AE034) and higher grade (P = 0AE044) bleeding in the PR-PASIII group (Tables V). Distribution of bleeding sites was not different between the study groups. Fourteen of the bleeding patients were on anticoagulant therapy at the time of bleeding, without differences between the groups. We did not observe lethal bleeding complications in the on protocol period; however, one patient in the PR-PASIII arm deceased due to intracranial bleeding after going off-protocol. We did not find an association between platelet dose, storage time or c-irradiation and the occurrence of bleeding (all grades). There were no differences between the groups with regard to number of RBC transfusions received. The mean number of RBC transfusions in the plasma group was 4 ± 3 as compared to 5 ± 3 and 4 ± 3 in the PASIII and PR-PASIII group, respectively. Twenty-eight mostly mild transfusion reactions occurred in 25 patients, without significant differences between groups (Tables V). Incidences of infections and SAE's were equally distributed among the groups. Three SAE's were possibly related to PC transfusion, one in each group. In the plasma group, one patient developed a severe, generalized skin reaction, a possible case of transfusionrelated acute lung injury was reported in the PASIII arm and, in the PR-PASIII arm, one patient developed acute glottis oedema that was treated successfully with antihistamines and steroids.
Discussion
In a non-selected population of thrombocytopenic haematology patients we studied the transfusion efficacy of PR-PASIII-PCs and PASIII-PCs in terms of increments, transfusion failures, PC consumption and transfusion interval as well as bleeding occurrence and adverse transfusion reactions, compared to plasma-PC. In accordance with the SPRINT trial but in contrast to the EuroSPRITE trial, we observed inferiority of transfusions with PR-PASIII-PC with regard to all transfusion efficacy-related endpoints (van Rhenen et al, 2003; McCullough et al, 2004) . Moreover more patients in the PR-PASIII-PC arm experienced bleeding complications. As reported previously, both study products contained less platelets due to loss of platelets during the production process ( not adequately correct for dose differences between arms, linear regression analysis of the post-transfusion platelet counts were performed using the covariates of treatment arm, platelet content and storage time, which also showed an independent effect of PR-PASIII PC (Davis et al, 1999) .
Using the linear regression analysis we estimated that a PR-PASIII-PC would need to contain an average of 200 · 10 9 platelets extra (i.e. approximately 3 BCs) to achieve a comparable count increment. The relationship between storage time for both CCIs showed a constant difference at each incremental day of storage, suggesting the decreased viability of a fixed number of platelets and normal disappearance of surviving platelets after treatment with this PR technique. To the same extent as plasma PC, PASIII PC showed a decrease in transfusion efficacy up to 7 d of storage and no difference in bleeding complications. Our results with regard to lower increments are in agreement with the SPRINT study. The Table III . Linear regression analysis 1-and 24-h platelet counts.
1-h platelet count
24-h platelet count Beta* P-value Beta P-value Table IV . Relation between covariates and the CCI-1 and CCI-24 adjusted for arm.
1-h CCI
24-h CCI Beta* (SE) P-value Beta (SE) P-value
Univariate random effects regression analysis adjusted for arm. All covariates, with the exception of storage time and patient age, are no/yes covariates. SE, standard error; TRF, transfusion; RBC, red blood cell concentrate. *Beta: regression coefficient. Except for the number of bleeding episodes, the numbers in the table reflect numbers (percentage) of patients. For the grades of bleeding and infections the maximum grade is used in case of more than one bleeding episode or more than one infection. *P = 0AE034 as compared to plasma. One patient died in the plasma arm 24 d after the last transfusion (the fifth) without serious adverse event (SAE) report. The cause of death was reported on the off study form as related to the treatment of the underlying disease, with fever presumably due to sepsis.
Clinical Effectiveness of Amotosalen-HCl/UVA Treated PC ª 2010 Blackwell Publishing Ltd, British Journal of Haematology discordance with the EuroSPRITE as well as with a large phase IV trial may be due to the usage of PC stored in PASII in approximately half of the reference group attenuating the results of the reference groups in these other studies (van Rhenen et al, 2003; Osselaer et al, 2009) .
Patients in the PR-PASIII group experienced more bleeds and more grade ‡2 bleeding compared with both the other arms. The EuroSPRITE and the other smaller European RCT reported no differences between the study arms with regard to bleeding complications (van Rhenen et al, 2003; Janetzko et al, 2005) . However, in the extended safety report of the SPRINT trial the frequency of grade 2-4 bleeding appeared significantly higher in the PR-arm, 43% as compared to 34% in the control arm (P = 0AE02) (Snyder et al, 2005) . It is unlikely that the difference in bleeding complications could be solely explained by a lower platelet dose resulting in lower post transfusion platelet peak levels. Estimating that approximately one-third of platelets were non-viable in PR-PC, the platelet dose was still comparable with the low to medium dose applied in a recently presented platelet dose trial, which showed that bleeding complications did not differ between low, medium or high dose levels of platelets transfused (Slichter et al, 2010) . Possibly, damage of platelet mitochondrial nucleic acids by PR may not only result in loss of viability of a proportion of platelets, but may also impair haemostatic capacity (Keuren et al, 2006; Apelseth et al, 2007) . We did not find significant differences in transfusion reactions, as observed in larger trials using PR-PASIII PC (Osselaer et al, 2008a, b) .
This study has some shortcomings
The number of off-protocol transfusions in the PR-PASIII arm could be regarded as an important limitation of our study. However, performances of both an ITT as well as a PP analysis lead to similar conclusions. The open label aspect of our study was not expected to influence platelet counts, the primary endpoint of our study, although we cannot completely exclude bias with regard to evaluation of bleeding.
In conclusion, although there are clear advantages and arguments in favour of PR techniques to increase transfusion safety, our results warrant their reappraisal prior to routine implementation. The process of PR using amotosalen-HCl/ UVA probably leads to decreased platelet viability and perhaps compromises haemostatic function, the primary goal of platelet transfusions in high risk patients. A comprehensive survey on the nature and consequences of amotosalen-HCl/ UVA-induced platelet damage is needed to understand how this damage can be compensated for in routine transfusion practice.
